Recent Advances in ECG Analysis for ProArrhythmia Risk Assessment: The Need to Read Between the Line

In the last 5 years, FDA has actively characterized innovative ECG analysis methods for proarrhythmia assessments in clinical trials. ECG is a cornerstone of cardiac safety monitoring in toxicology and safety pharmacology with similarities between clinical and non-clinical evaluations.

A presentation was given by CitoxLab North America during SOT Annual Meeting & ToxExpo 2019, in Baltimore:

Recent Advances in ECG Analysis for ProArrhythmia Risk Assessment: The Need to Read Between the Line

 

Other posts you may like

American College of Toxicology

November 17-20, 2019 Phoenix, AZ - USA Booth #207

American Physiology Society

October 28, 2019 Washington, DC USA

Leveraging Machine Learning for Automated ECG and Hemodynamic Analyses

Download the presentation from Amgen (SPS 2019)

Association of Inhalation Toxicologists

October 14-16 2019 Brighton, East Sussex United Kingdom